Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 5/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27900519 | 0.76 | PKM (0.45) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL17286127 | 0.75 | TSHR (0.37) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL22435051 | 0.74 | HTR2A (0.34) | CYP2C19MEN1KMT2ACYP1A2TSHR | |
| SCHEMBL27414838 | 0.70 | — | — | |
| SCHEMBL22458878 | 0.70 | — | — | |
| SCHEMBL18244899 | 0.69 | CYP2C19 (0.47) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL707693 | 0.69 | TSHR (0.30) | TSHR | |
| SCHEMBL22856847 | 0.69 | — | — | |
| SCHEMBL420603 | 0.67 | — | — | |
| SCHEMBL27286241 | 0.67 | CYP2C19 (0.45) | CYP2C19MEN1GLAKMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851073-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | ABBVIE INC. (US) | 2020-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851073-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | PTPN1, PTPN2, PTPN18 | CYP2C19 4034/4885MEN1 3734/4885GLA 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.